SecBot SecBot
PRESS-RELEASE ·Filed Aug 12, 2026

RVPH

Reviva Pharmaceuticals
NEUTRAL
Impact 4/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The key catalyst is the FDA feedback in Q4 2026 on the new brilaroxazine formulation, which will determine the path for the RECOVER-2 trial and NDA. The company's cash runway and ability to secure additional financing before 1H 2027 enrollment are critical to monitor.

DirectionNeutral
Confidencemedium
Horizonmonths

Drugs in focus

RVPH drug pipeline →

brilaroxazine

◆ Mixed Named in this press release
Impact
Phase
Phase 3
Time to market
If approved, brilaroxazine is at least 3-5 years from potential commercialization. RECOVER-2 enrollment is expected to begin in 1H 2027 (subject to financing), followed by a multi-year trial, NDA submission, and FDA review.
Next catalyst
None dated

What to watchThe immediate catalyst is FDA feedback on the new brilaroxazine formulation, expected in Q4 2026 (any day now). Positive feedback would clear a path for RECOVER-2 and NDA; negative feedback or a request for more data would likely pressure the stock further. Separately, the company needs to raise additional capital before RECOVER-2 enrollment can begin in 1H 2027, and its OTCQB listing limits financing options.

How the stock moved after the report

NEUTRAL VIEWSTOCK AT ENTRY AT T+60
Entry
$0.3521
T+0 close · Aug 12, 2026 · via day close
Latest settled
0.00%
T+60 · $0.3521
Vs SPY
+5.48%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 13 $0.3521entry
  2. T+1 · 3mo ago 0.00%α +0.20% · $0.3521
  3. T+5 · 3mo ago 0.00%α +1.96% · $0.3521
  4. T+20 · 2mo ago 0.00%α +1.75% · $0.3521
  5. T+60 · 11d ago 0.00%α +5.48% · $0.3521

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Reviva Pharmaceuticals reported a Q2 2026 net loss of $2.4 million ($0.19 per share), narrower than the year-ago loss of $6.1 million ($2.40 per share), and ended the quarter with $19.9 million in cash. The company is awaiting FDA feedback in Q4 2026 on using a new brilaroxazine formulation in its RECOVER-2 Phase 3 trial and NDA, with patient enrollment expected to begin in 1H 2027 subject to additional financing.

Key Financial Metrics

EPS
−$0.19
Revenue
$0.00
est $0.00

Key Facts

  • Net loss of $2.4 million ($0.19 per share) for Q2 2026 vs. $6.1 million ($2.40 per share) for Q2 2025.
  • Cash and cash equivalents of $19.9 million as of June 30, 2026, up from $14.4 million as of December 31, 2025.
  • FDA feedback on new brilaroxazine formulation for RECOVER-2 trial and NDA expected Q4 2026.
  • Patient enrollment in RECOVER-2 Phase 3 trial expected to initiate in 1H 2027, subject to additional financing.
  • U.S. composition of matter patent application filed for a new form of brilaroxazine, aiming to extend exclusivity through 2046.

Financial Impact

Net loss improved by $3.6 million year-over-year; cash position increased by $5.5 million since year-end 2025.

net losscash and cash equivalents

Risk Factors

  • Patient enrollment in RECOVER-2 is contingent on additional financing, which may not be secured.
  • The company's stock trades on OTCQB, which may limit liquidity and access to capital.
  • No revenue generated; reliance on dilutive financing to fund operations.

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3344112

Track record

12 reports on RVPH

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +22.98% at T+20 after the Jul 10, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 3/10 No price data
  2. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.3400 Now $0.3504 +3.07% settles Feb 11
  3. Nov 9, 20267d ago DEF 14A Neutral 4/10 Entry $0.3521 Now $0.3504 −0.47% settles Feb 8
  4. Aug 12, 202613w ago Press Release Neutral 4/10 Viewing Entry $0.3521 to $0.3521 Now $0.3504 −0.47% · 0.00% +5.48% vs SPY
  5. Jul 10, 202618w ago 25-NSE Bearish 7/10 Entry $0.6200 to $0.5000 Now $0.3504 +43.48% ▲ +19.35% +22.24% vs SPY
  6. May 13, 202626w ago Press Release Bearish 7/10 Entry $0.3900 to $0.4303 Now $0.3504 +10.14% ▼ −10.33% −6.74% vs SPY
  7. May 13, 202626w ago 8-K Bearish 8/10 Entry $0.3521 to $0.4775 Now $0.3504 +0.47% ▼ −35.62% −31.19% vs SPY
  8. Apr 15, 202630w ago 8-K Neutral 5/10 Entry $0.8900 to $0.5731 Now $0.3504 −60.62% ▼ −35.61% −43.74% vs SPY
  9. Mar 30, 202633w ago Press Release Mixed 6/10 Entry $0.6600 to $0.6000 Now $0.3504 −46.90% ▼ −9.09% −25.58% vs SPY
  10. Mar 18, 202634w ago Press Release Bearish 6/10 Entry $0.8300 to $0.7000 Now $0.3504 +57.78% ▲ +15.66% +30.01% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens Wed (11h 7m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 12, 2026